Drugs / Sodium laurel sulfate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04882631 Background | Apr → May 2021 | — | Pyramid Biosciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium laurel sulfate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04882631 ↗ |
| Known as | SLS | “Positive Control - Sodium laurel sulfate (SLS)” NCT04882631 ↗ |
| Route | Topical | “Approximately 0.4 mL of 0.25% SLS was applied daily (excluding weekends) as a positive control test site.” NCT04882631 ↗ |